Healthcare investment firm Catalio Capital Management has held the final close of its second credit fund, raising more than $325m (£241.8m) and exceeding its $250m fundraising target.
The Catalio Structured Opportunities Fund II invests in healthcare companies to address “capital scarcity” in market financing. It focuses on commercial-stage businesses with scientific and clinical expertise, with investments spanning senior secured debt to structured equity.
Read more: Adams Street closes $350m private credit CLO
“We greatly appreciate the commitment of our investors, many of whom have supported our vision from day one,” said John Henry Iucker, founding partner and head of credit at Catalio. “The Catalio Structured Opportunities Fund provides innovative healthcare companies with flexible capital at a critical stage of their growth and commercial execution.”
Catalio said the strategy has completed 21 investments to date. Investments made through the second fund include a $20m credit investment in Leo Cancer Care’s $40m funding round and a $20m credit investment in Amalgam Rx to accelerate the scaling of medical-grade AI solutions.
Read more: Monroe Capital closes fifth private credit fund at $6.1bn
The New York-based investment firm, which manages more than $2bn in assets, launched its first private credit fund in 2022, raising $85m.
